Omidenepag Explained

Jan:Omidenepag isopropyl
Tradename:Eybelis, Omlonti
Routes Of Administration:Topical eye drops
Atc Prefix:S01
Atc Suffix:EX06
Legal Us:Rx-only
Legal Us Comment:[1] [2]
Legal Status:Rx-only
Cas Number:1187451-41-7
Cas Number2:1187451-19-9
Pubchem:44230575
Pubchem2:44230999
Drugbank:DB15071
Chemspiderid:44210451
Chemspiderid2:57643658
Unii:Z95F9F9LU4
Unii2:G0G0H52U6K
Kegg:D10965
Kegg2:D10966
Chembl:3707245
Chembl2:4297666
Synonyms:UR-7276, DE-117
Iupac Name:Propan-2-yl 2-6-(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylaminomethyl]pyridin-2-ylamino]acetate
C:26
H:28
N:6
O:4
S:1
Smiles:CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1
Stdinchi:1S/C23H22N6O4S/c30-23(31)15-25-22-6-1-4-19(27-22)17-28(34(32,33)21-5-2-11-24-14-21)16-18-7-9-20(10-8-18)29-13-3-12-26-29/h1-14H,15-17H2,(H,25,27)(H,30,31)
Stdinchi2:1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30)
Stdinchikey:YHGSTSNEOJUIRN-UHFFFAOYSA-N
Stdinchikey2:VIQCWEGEHRBLAC-UHFFFAOYSA-N

Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.

Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022.[3]

Medical uses

Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.[4]

Adverse effects

The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.[4]

Pharmacology

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.[5] Omidenepag is a selective prostaglandin E2 receptor agonist.[6] [7]

History

Omidenepag was developed by Ube Industries and Santen Pharmaceutical.[4]

External links

Notes and References

  1. Web site: Omlonti- omidenepag isopropyl solution/ drops . DailyMed . 30 September 2022 . 16 October 2022.
  2. Web site: Drug Approval Package: Omlonti . U.S. Food and Drug Administration (FDA) . 20 October 2022 . 4 December 2022.
  3. Santen and UBE Received FDA Approval for Omlonti (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension . Santen . Business Wire . 26 September 2022 . 1 October 2022.
  4. Duggan S . Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval . Drugs . 78 . 18 . 1925–1929 . December 2018 . 30465134 . 10.1007/s40265-018-1016-1 . 53721056 .
  5. Web site: Omidenepag isopropyl . DrugCentral . Division of Translational Informatics at University of New Mexico . 8 January 2022 . 8 January 2022 . https://web.archive.org/web/20220108225107/https://drugcentral.org/drugcard/5312 . live .
  6. Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, Shimazaki A, Matsugi T, Shams N, Zhang JZ . 6 . Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent . Investigative Ophthalmology & Visual Science . 59 . 1 . 145–153 . January 2018 . 29332128 . 10.1167/iovs.17-22745 . free .
  7. Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H . Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells . Scientific Reports . 10 . 1 . 16018 . September 2020 . 32994409 . 7524797 . 10.1038/s41598-020-72538-x . 2020NatSR..1016018I .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Omidenepag".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.